IP Library › Granted Patent US 12,286,476
Granted Patent B2
US 12,286,476 · App. 17/430,311 · Granted Apr 29, 2025

FCMR-binding molecules and uses thereof

Inventors: Richard Brokx (Toronto, CA); Jacqueline M. Mason (Toronto, CA); Mark R. Bray (Toronto, CA)
Assignee: UNIVERSITY HEALTH NETWORK
C07K16/2803A61P35/02C12N15/63C07K2317/73C07K2317/74C07K2317/75C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,286,476
App. No.
17/430,311
Granted
Apr 29, 2025
Kind
B2
Abstract

The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

Claims (45)

1. An antibody that binds human FCMR, the antibody comprising a heavy chain variable region comprising vhCDR1-3, and a light chain variable region comprising vlCDR1-3, wherein the CDRs are selected from the following:

a) a vhCDR1 comprising SEQ ID NO:13, a vhCDR2 comprising SEQ ID NO:14, a vhCDR3 comprising SEQ ID NO:15, a vlCDR1 comprising SEQ ID NO:16, a vlCDR2 comprising the amino acid sequence RAN, and a vlCDR3 comprising SEQ ID NO:18;

b) a vhCDR1 comprising SEQ ID NO:19, a vhCDR2 comprising SEQ ID NO:20, a vhCDR3 comprising SEQ ID NO:21, a vlCDR1 comprising SEQ ID NO:22, a vlCDR2 comprising the amino acid sequence RAN, and a vlCDR3 comprising SEQ ID NO:24;

c) a vhCDR1 comprising SEQ ID NO:25, a vhCDR2 comprising SEQ ID NO:26, a vhCDR3 comprising SEQ ID NO:27, a vlCDR1 comprising SEQ ID NO:28, a vlCDR2 comprising the amino acid sequence RAN, and a vlCDR3 comprising SEQ ID NO:30;

d) a vhCDR1 comprising SEQ ID NO:31, a vhCDR2 comprising SEQ ID NO:32, a vhCDR3 comprising SEQ ID NO:33, a vlCDR1 comprising SEQ ID NO:34, a vlCDR2 comprising the amino acid sequence GAS, and a vlCDR3 comprising SEQ ID NO:36;

e) a vhCDR1 comprising SEQ ID NO:37, a vhCDR2 comprising SEQ ID NO:38, a vhCDR3 comprising SEQ ID NO:39, a vlCDR1 comprising SEQ ID NO:40, a vlCDR2 comprising the amino acid sequence LVS, and a vlCDR3 comprising SEQ ID NO:42; or

f) a vhCDR1 comprising SEQ ID NO:43, a vhCDR2 comprising SEQ ID NO:44, a vhCDR3 comprising SEQ ID NO:45, a vlCDR1 comprising SEQ ID NO:46, a vlCDR2 comprising the amino acid sequence GAV, and a vlCDR3 comprising SEQ ID NO:48.

2. The antibody according to claim 1 , wherein the antibody comprises a constant region with an amino acid sequence at least 90% identical to a human IgG.

3. The antibody according to claim 2 , wherein the human IgG is selected from a group consisting of IgG1, IgG2, IgG3 and IgG4.

4. The antibody according to claim 3 , wherein the IgG is an IgG2.

5. The antibody according to claim 3 , wherein the IgG is an IgG1.

6. A nucleic acid composition encoding the antibody according to claim 1 , wherein a first nucleic acid encodes the heavy chain variable region, and wherein a second nucleic acid encodes the light chain variable region.

7. An expression vector composition comprising the nucleic acid composition according to claim 6 , wherein the first nucleic acid is contained in a first expression vector and the second nucleic acid is contained in a second expression vector.

8. An expression vector composition comprising the nucleic acid composition according to claim 6 , wherein the first nucleic acid and the second nucleic acid are contained in a single expression vector.

9. A host cell comprising the expression vector composition of claim 7 .

10. A host cell comprising the expression vector composition of claim 8 .

11. A method of making an antibody comprising culturing said host cell of claim 9 under conditions wherein the antibody is expressed, and recovering the antibody.

12. A composition comprising the antibody according to claim 1 , and a pharmaceutical acceptable carrier or diluent.

13. A method of modulating an immune response in a subject, the method comprising administering to the subject an effective amount of the antibody according to claim 1 or a nucleic acid composition encoding said antibody.

14. The method of claim 13 , wherein the method stimulates an immune response in a subject.

15. The method of claim 13 , wherein the method inhibits an immune response in a subject.

16. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody according to claim 1 or a nucleic acid composition encoding said antibody.

17. The method according to claim 16 , wherein the cancer is a B cell malignancy.

18. The method according to claim 16 , wherein the cancer is chronic lymphocytic leukemia.

19. The method according to claim 16 , wherein the antibody is combined with one or more additional cancer therapeutic agents.

20. The method according to claim 19 , wherein the additional cancer therapeutic agents are immune checkpoint inhibitors.

21. The method according to claim 20 , wherein the immune checkpoint inhibitors are selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, and a LAG-3 inhibitor.

22. A method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody according to claim 1 or a nucleic acid composition encoding said antibody.

23. The method according to claim 22 , wherein the antibody is combined with one or more additional anti-inflammatory therapeutic agents.

24. A method of treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody according to claim 1 or a nucleic acid composition encoding said antibody.

25. The method according to claim 24 , wherein the antibody is combined with one or more antibiotic therapeutic agents.

26. A method of treating a viral infection in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody according to claim 1 or a nucleic acid composition encoding said antibody.

27. The method according to claim 26 , wherein the antibody is combined with one or more anti-viral therapeutic agents.

28. A method of modulating FCMR in a subject, the method comprising administering to the subject an effective amount of the antibody according to claim 1 or a nucleic acid composition encoding said antibody.

29. The method of claim 28 , wherein modulating FCMR inhibits FCMR activity.

30. The method of claim 28 , wherein modulating FCMR promotes FCMR activity.

31. The antibody of claim 1 , the antibody comprising a vhCDR1 comprising SEQ ID NO:13, a vhCDR2 comprising SEQ ID NO:14, a vhCDR3 comprising SEQ ID NO:15, a vlCDR1 comprising SEQ ID NO:16, a vlCDR2 comprising the amino acid sequence RAN, and a vlCDR3 comprising SEQ ID NO:18.

32. The antibody that binds human FCMR according to claim 1 , the antibody comprising:

a) a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:1 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:2;

b) a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:3 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:4;

c) a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:5 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:6;

d) a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:7 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:8;

e) a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:9 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:10; or

f) a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:11 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:12.

33. The antibody of claim 31 , the antibody comprising a heavy chain variable region comprised in amino acid sequence of SEQ ID NO:1 and a light chain variable region comprised in amino acid sequence of SEQ ID NO:2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2022
From: BROKX, RICHARD; MASON, JACQUELINE M.; BRAY, MARK R.
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 059785/0653 →
Continuity (2)
Provisional Application 62806237 · Feb 15, 2019
Related Publication 20220089725A1 · Mar 24, 2022
References Cited (58)
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 7657380B2 · Lazar et al. · 2010 [cited by applicant]
US 10023648B2 · Hombach et al. · 2018 [cited by applicant]
US 20140271629A1 · Corbit · 2014 [cited by examiner]
US 20160244525A1 · Yin et al. · 2016 [cited by applicant]
US 20160347854A1 · Hombach et al. · 2016 [cited by applicant]
WO WO9211018A1 · 1992 [cited by applicant]
WO WO2013136193A2 · 2013 [cited by applicant]
WO WO2015000059A1 · 2015 [cited by applicant]
WO WO2016127247A1 · 2016 [cited by applicant]
WO WO2018119425A2 · 2018 [cited by applicant]
WO WO2020163962A1 · 2020 [cited by applicant]
Baca, Manuel et al., “Antibody Humanization Using Monovalent Phage Display,” J. Biol. Chem., Apr. 18, 1997, 272(16):10678-10684. [cited by applicant]
Baeuerle, Patrick A. et al., “NF-κB: Ten Years After,” Cell, Oct. 4, 1996, 87:13-20. [cited by applicant]
Baldwin, Albert S., Jr. et al., “The NF-κB and IκB Proteins: New Discoveries and Insights,” Ann. Rev. Immunol., 1996, 12:141. [cited by applicant]
Carter, Paul et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Natl. Acad. Sci. USA, May 1992, 89:4285-4289. [cited by applicant]
Dayhoff, Margaret O., “Atlas of Protein Sequence and Structure,” National Biomedical Research Foundation, 1978, 5(3):353-358. [cited by applicant]
De Pascalis, Roberto et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal An… [cited by applicant]
Edelman, Gerald M. et al., “The Covalent Structure of an Entire γG Immunoglobulin Molecule,” Proc. Natl. Acad. Sci. USA, Mar. 21, 1969, 63:78-85. [cited by applicant]
Gorman, Scott D. et al., “Reshaping a therapeutic CD4 antibody,” Proc. Natl. Acad. Sci. USA, May 1991, 88:4181-4185. [cited by applicant]
Gribskov, Michael et al., “Sigma factors from [cited by applicant]
He, Xing-Yue et al., “Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin,” J. Immunol., 1998, 160: 1029-1035. [cited by applicant]
International Search Report and Written Opinion mailed Apr. 24, 2020 in International Application No. PCT/CA20/50195. [cited by applicant]
Jefferis, Roy et al., “Interaction sites on human IgG-Fc for FcgR: current models,” Immunol. Lett., 2002, 82:57-65. [cited by applicant]
Jones, Peter T. et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, May 29, 1986, 321:522-525. [cited by applicant]
Krauss, Jürgen et al., “Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment,” Protein Engineering, 2003, 16… [cited by applicant]
Langer, Robert, “New Methods of Drug Delivery,” Sep. 28, 1990, Science, 249:1527-1533. [cited by applicant]
O'Connor, Shane J. et al., “Humanization of an antibody against human protein C and calcium-dependence involving framework residues,” Protein Engineering, 1998, 11(4):321-328. [cited by applicant]
Presta, Leonard G. et al., “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders,” Cancer Res., Oct. 15, 1997, 57(20):4593-4599. [cited by applicant]
Queen, Cary et al., “A humanized antibody that binds to the interleukin 2 receptor,” Dec. 1989, Proc. Natl. Acad. Sci, USA, 86:10029-10033. [cited by applicant]
Rader, Christoph et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,” Proc. Natl. Acad. Sci. USA, Jul. 1998, 95: 8910-8915. [cited by applicant]
Riechmann, Lutz et al., “Reshaping human antibodies for therapy,” Nature, Mar. 24, 1988, 332:323-327. [cited by applicant]
Roguska, Michael A. et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” Proc. Natl. Acad. Sci. USA, Feb. 1994, 91:969-973. [cited by applicant]
Roque, A. Cecilia A. et al., “Antibodies and Genetically Engineered Related Molecules: Production and Purification,” 2004, Biotechnol. Prog., 20:639-654. [cited by applicant]
Rosok, Mae Joanne et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” J. Biol. Chem, Sep. 13, 1996, 271(37): 22611-22618. [cited by applicant]
Schmitz, Gerd et al., “Pharmacogenomics: implications for laboratory medicine,” Clinica Chimica Acta, 2001, 308:43-53. [cited by applicant]
Smith, Temple F. et al., “Comparison of Biosequences,” Advances in Applied Mathematics, 1981, 2:482-489. [cited by applicant]
Steimer, Werner et al., “Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy,” Clinica Chimica Acta, 2001, 308: 33-41. [cited by applicant]
Tan, Philip et al., “‘Superhumanized’ Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28,” J. Immunol., 2002, 169:111… [cited by applicant]
Tsurushita, Naoya, et al., “Humanization of Monoclonal Antibodies,” Molecular Biology of B Cells, Elsevier Science (USA), 2004, 533-545. [cited by applicant]
Verhoeyen, Martine et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, Mar. 25, 1988, 239:1534-1536. [cited by applicant]
Wu, Herren et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” 1999, J. Mol. Biol. 294:151-162. [cited by applicant]
Ye, Jian et al., “IgBLAST: an immunoglobulin variable domain sequence analysis tool,” Nucleic Acids Research, 2013, 41:W34-W40. [cited by applicant]
Pallasch, C. et al., “Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease,” Blood, Nov. 15, 2008, 112(10):4213-4219. [cited by applicant]
Tan, Y. et al., “Anti-TOSO antibody treatment promotes T cell activation-induced cell death (AICD) in vitro and in vivo,” Chin. Sci. Bull., Immunology, Science China Press, 2014, 59(13):1374-1385. [cited by applicant]
Kubagawa, Y. et al., “Monoclonal Antibodies Specific for Human IgM Fc Receptor Inhibit Ligand-binding Activity,” Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2014, 33(6):393-400. [cited by applicant]
Nguyen, X.et al., “Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination,” Immunobiology, Blood, Jul. 21, 2011, 118(3):598-608. [cited by applicant]
Yi, T. et al., “Anti-TOSO antibody treatment promotes T cell activation-induced cell death (AICD) in vitro and in vivo,” Chinese Science Bulletin, 2014, 59:1374-1385. [cited by applicant]
First Office Action for corresponding Chinese Patent Application No. 202080025378, dated Jun. 27, 2024, 13 pages, English translation. [cited by applicant]
EPC Rule 94(3) Communication for corresponding European Patent Application No. 20756467.5, dated Aug. 19, 2024, 5 pages. [cited by applicant]